Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

24 juin 2023 08h00 HE | Source: Enterin, Inc.

Enterin Presents Data Demonstrating Strong Benefit of ENT-03 on Body Weight, Adiposity and Blood Glucose Vs. Semaglutide in a Diet Induced Obesity Mouse Model

PHILADELPHIA, June 24, 2023 (GLOBE NEWSWIRE) -- Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative and...
05 juin 2023 08h00 HE | Source: Enterin, Inc.

Enterin Announces the Start of a First-in-Human Study of ENT-03 in Obesity and Type 2 Diabetes

PHILADELPHIA, June 05, 2023 (GLOBE NEWSWIRE) -- Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative and...
31 mai 2023 10h01 HE | Source: Enterin, Inc.

Enterin announces FDA acceptance of an investigator sponsored IND to treat a patient with prodromal multisystem atrophy (MSA) with ENT-01

PHILADELPHIA, May 31, 2023 (GLOBE NEWSWIRE) -- Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative and...
13 oct. 2022 00h15 HE | Source: Enterin, Inc.

Enterin and Parkinson’s UK Announce Research Collaboration in Parkinson’s Dementia

PHILADELPHIA, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company developing novel treatments for neurodegenerative and...
03 oct. 2022 08h00 HE | Source: Enterin, Inc.

Enterin Announces New Funding and Appointment of David Vogel to Its Board of Directors

PHILADELPHIA, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company developing novel treatments for neurodegenerative and...